The cytosolic 5'-nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells. by Bricard, G et al.
Oncotarget67380www.impactjournals.com/oncotarget
The cytosolic 5’-nucleotidase cN-II lowers the adaptability to 
glucose deprivation in human breast cancer cells
Gabriel Bricard1,*, Octavia Cadassou1,*, Laure-Estelle Cassagnes1, Emeline Cros-
Perrial1, Léa Payen-Gay1,2, Jean-Yves Puy3, Isabelle Lefebvre-Tournier3, Maria 
Grazia Tozzi4, Charles Dumontet1 and Lars Petter Jordheim1
1Université De Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche 
en Cancérologie de Lyon, Lyon, France
2Biochemistry Laboratory of Lyon Sud, Hospices Civils de Lyon, Lyon, France
3IBMM, UMR 5247, CNRS - UM - ENSCM, Université de Montpellier, Montpellier, France
4Department of Biology, Biochemistry Unit, University of Pisa, Pisa, Italy
*These authors have contributed equally to this work
Correspondence to: Lars Petter Jordheim, email: lars-petter.jordheim@univ-lyon1.fr
Keywords: 5’-nucleotidase, reactive oxygen species, glucose metabolism, hypoxia
Received: March 15, 2017     Accepted: May 22, 2017     Published: June 27, 2017
Copyright: Bricard et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
The cytosolic 5’-nucleotidase cN-II is a highly conserved enzyme implicated in 
nucleotide metabolism. Based on recent observations suggesting additional roles not 
directly associated to its enzymatic activity, we studied human cancer cell models with 
basal or decreased cN-II expression. We developed cancer cells with stable inhibition 
of cN-II expression by transfection of shRNA-coding plasmids, and studied their 
biology. We show that human breast cancer cells MDA-MB-231 with decreased cN-II 
expression better adapt to the disappearance of glucose in growth medium under 
normoxic conditions than cells with a baseline expression level. This is associated 
with enhanced in vivo growth and a lower content of ROS in cells cultivated in absence 
of glucose due to more efficient mechanisms of elimination of ROS. Conversely, 
cells with low cN-II expression are more sensitive to glucose deprivation in hypoxic 
conditions. Overall, our results show that cN-II regulates the cellular response to 
glucose deprivation through a mechanism related to ROS metabolism and defence.
INTRODUCTION
The hallmarks of cancer include genome instability 
and mutations, leading to deregulated energetic 
homeostasis, sustained proliferative signaling and escape 
from immune surveillance [1]. These major characteristics 
are all influenced by nucleoside metabolism as shown 
by: i) increased rate of genomic modifications when 
nucleotide pools are deregulated [2], ii) the important role 
of nucleotide derivatives as sources of energy for the cell 
and intracellular signaling effectors, and iii) the tumor- 
and immuno-modulating roles of adenosine and ATP [3, 
4]. Therefore, nucleotide metabolism has become a subject 
of major interest in cancer research and constitutes a 
potential target for anticancer therapy.
5’-nucleotidases are involved in nucleotide 
metabolism by dephosphorylating nucleoside 
monophosphates into nucleosides and inorganic phosphate. 
There are today eight different human 5’-nucleotidases 
described, and they differ by their subcellular localization, 
substrate affinities and regulatory mechanisms [5, 6]. The 
cytosolic enzyme cN-II has a preference for IMP and 
GMP and has also been described as being capable of 
phosphorylating nucleosides through a phosphotransferase 
activity [7]. We have previously shown that this enzyme 
is involved in the sensitivity of cancer cells to nucleoside 
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analogue-based chemotherapy [8, 9], and developed 
and studied enzymatic inhibitors [10–14]. The clinical 
relevance of this approach has been confirmed by the 
observation of hyperactive cN-II mutants in relapsed 
pediatric acute lymphoblastic leukemia patients associated 
with a resistance to purine analogues [15, 16]. However, 
very little is known about the overall physiological role 
of cN-II in cells, and especially in cancer cells from 
solid tumors. Transient inhibition of its expression in 
neuroblastoma cells by siRNA indicated a role in cell 
survival as this was associated with induction of apoptosis 
[17], whereas a similar decrease in skeletal muscle cells 
induced activation of AMPK (which regulates lipid and 
glucose metabolism) as well as modified lipid metabolism 
and glucose transport [18]. In addition, stable up- or down-
regulation of cN-II expression in various cancer cells has 
shown its implication in cell proliferation even though this 
is not the case for all cell lines [9, 19, 20]. Finally, the 
recently demonstrated interaction between cN-II and the 
inflammasome-protein NLRC4/Ipaf suggests other and 
still unknown properties of this enzyme in cell biology 
that could be independent of its enzymatic activity [21].
In this study, we show that cN-II decreases the 
capacity to manage intracellular levels of reactive oxygen 
species (ROS), suggesting an important role of this protein 
in cell biology.
RESULTS
Transfected cells have decreased cN-II 
expression and enzymatic activity
The pScN-II cell models used in this study have 
previously been shown to have decreased cN-II protein 
expression [19]. This modification in protein expression 
was associated with a 1.3-2.2-fold decrease in specific 
enzymatic activity in all cell lines. Indeed, the specific 
enzymatic activity (nmol of inosine produced by minute 
per milligram of protein) in presence of ATP was 2.49 ± 
0.20 for MDA-MB-231-pScont vs. 1.15 ± 0.04 for MDA-
MB-231-pScN-II; 5.49 ± 0.75 for HCT-116-pScont vs. 
2.89 ± 0.50 for HCT-116-pScN-II; 1.85 ± 0.25 for NCI-
H292-pScont vs. 1.46 ± 0.16 for NCI-H292-pScN-II; 1.98 
± 0.14 for MIA PaCa-2-pScont vs. 1.33 ± 0.02 for MIA 
PaCa-2-pScN-II.
Decreased cN-II expression is associated with 
enhanced in vivo xenograft growth
Initial experiments of in vitro proliferation of the 
transfected models by CFSE titration did not show any 
differences between pScont and pScN-II cells [19]. We 
here continued the characterization with the evaluation of 
tumor growth in scid mice after the injection of 5 million 
cells subcutaneously. As indicated in Figure 1, the growth 
of pScN-II cells was consistently more rapid than for 
pScont cells in the four different models evaluated. This 
difference was modest and statistically significant for MIA 
PaCa-2 cells at day 27, suggesting that stably reduced 
content of cN-II in these cell models can favor tumor 
growth. Whereas tumors with NCI-H292, MIA PaCA-2 
and HCT-116 cells reached a volume of approximately 
1000 mm3 after 28 days, MDA-MB-231 cells grew more 
slowly.
pScN-II cells have modified in vitro growth as 
compared to pScont cells
To investigate the proliferation and behavior of the 
transfected cells in vitro, we performed long-term cell 
culture with real-time assessment of proliferation and 
adherence capacity using the xCELLigence technology. 
In these experiments, the cell culture media was not 
changed during the culture. As indicated in Figure 2 for 
MDA-MB-231 cells, there is a clear shift in the cell index 
appearing after approximately 7 days of culture in media 
containing initially 25 mM glucose. These variations in 
growth curves are much less pronounced for pScN-II cells 
as compared to pScont cells, indicating a major difference 
in the behavior between the two cell lines in response to 
the modifications appearing at this moment. When the 
initial concentrations of glucose in the media were lower, 
the same event appeared earlier (5 days with 10 mM, 4 
days with 5 mM) and was always less pronounced for 
pScN-II cells. This suggested that the shift in cell index 
was associated with the disappearance of glucose in the 
culture medium. No interpretable growth curves were 
obtained with long term culture of any of the other cell 
models probably due to the rapid growth of these cells, 
and thus no glucose-dependent variations were observed. 
We therefore focused most of the further experiments on 
the MDA-MB-231 cell model.
Decreased cN-II expression does not modify 
glucose uptake or lactate secretion in vitro
As the MDA-MB-231-pScont and -pScN-II cells 
displayed different behavior in terms of cell index that 
was dependent on initial glucose concentration, we 
compared the glucose uptake and associated lactate 
secretion between the two cell models. When cells were 
seeded at the same ratio of cells/volume of media as 
in previous experiments and with 10 mM glucose, the 
glucose disappeared from the medium after 6 days of 
culture both for pScN-II and pScont cells (Figure 3). No 
notable differences in extracellular glucose concentration 
(reflecting glucose uptake) or in extracellular lactate 
concentrations (reflecting lactate secretion) were 
observed between the two cell lines when the cell 
number, as determined by direct counting, was taken 
into account. This suggested that the difference in cell 
behavior observed in Figure 2 was rather due to the 
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Figure 1: In vivo tumorigenesis of MDA-MB-231 (A), HCT-116 (B), NCI-H292 (C) and MIA PaCa-2 (D) pScont (■) and pScN-II cells 
(●). Tumor volumes are mean values from 3 mice per group and error bars are standard deviation. **: p<0.005 with Student’s t-test.
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ability of the different cells to adapt to culture media 
without glucose rather than to their use of glucose. In 
addition, as extracellular lactate levels reached 20 mM 
for an initial concentration of 10 mM glucose, it seems 
that the cells metabolized glucose preferentially through 
glycolysis rather than through oxidative phosphorylation.
pScN-II cells have lower content of ROS during 
long-term in vitro growth
When glucose is completely consumed, cells have 
to switch their metabolism towards the use of extracellular 
lactate as a carbon source or to beta-oxidation of fatty 
Figure 2: Long term in vitro cell growth of MDA-MB-231-pScont (■) and -pScN-II (●) cells in presence of 25 mM (A), 10 mM (B) or 5 
mM (C) glucose. Cells were seeded at 3000 cells per well in a final volume of 250 μl. Graphs show the normalized cell index during time 
(normalized on 5 hours).
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acids. Glutamine is another potential substrate but is highly 
unstable under our experimental conditions and is rapidly 
cleared from the culture medium. Lactate is transformed 
into pyruvate and acetyl-CoA while fatty acids release 
acetyl-CoA, which is further processed through the 
tricarboxylic acid cycle and oxidative phosphorylation in 
the mitochondrion. It has been shown that ROS-induced 
activation of AMPK further induces activation of pyruvate 
dehydrogenase kinase (PDK) and phosphorylation of 
pyruvate dehydrogenase (PDH) that stimulates lactate 
processing [22], and that AMPK stimulates beta-oxidation 
by ACC phosphorylation [23]. We propose that MDA-
MB-231-pScN-II cells are more prone to perform this 
shift from glucose metabolism to lactate metabolism or to 
beta-oxidation. However, the oxidative phosphorylation is 
reported to be associated with enhanced levels of reactive 
Figure 3: Cell number (A), glucose (B) and lactate (C) concentration in media during long term in vitro culture of MDA-MB-231-pScont 
(■) and -pScN-II (●) cells. Cells were seeded in 6-well plates (90 000 cells per plate) in media containing 10 mM glucose. Values are mean 
results of duplicates from a representative experiment and error bars are standard deviation.
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Figure 4: Cell number (A), ROS content (B) and cell death (C) in MDA-MB-231-pScont (■) and -pScN-II (●) cells cultivated long-term 
without (full lines) or with renewed glucose (dotted lines). Cells were seeded in 6-well plates (180 000 cells per well in 3 mL of media 
with 5 mM glucose) and glucose (5 mM) was renewed three times a week. In A-C, results are means of duplicates from a representative 
experiment and error bars are standard deviation. (D) ROS content in MDA-MB-231-pScont (black) and -pScN-II (grey) cells cultivated for 
3 days in media containing either 5 or 25 mM glucose or galactose or no sugar. Cells were seeded in 6-well plates (200 000 cells per well, 3 
mL of media) and adhered overnight before culture in indicated media. In (D), results are mean values of the ratio of MFI in each condition 
and the glucose 25 mM condition in three independent experiments and error bars are standard deviation. For both cell lines, Glc 0 mM and 
Gal 25 mM and Gal 5 mM were statistically significant (p<0.05, Student’s t-test) from Glc 25 mM, and for Glc 25 mM, Glc 5 mM, Glc 0 
mM and Gal 25 mM differences between pScont and pScN-II were statistically significant (p<0.05, Student’s t-test).
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oxygen species [24], which would rather be detrimental 
than beneficial for pScN-II cells. We therefore evaluated 
ROS levels in cells during cell culture simulating the 
conditions used during xCELLigence experiments. As 
shown in Figure 4A-4C, the ROS level increased in MDA-
MB-231-pScont cells some days after the disappearance of 
glucose in the cell culture media (approximately when cell 
growth reaches a plateau), whereas ROS levels remained 
lower in pScN-II cells. The increase in ROS levels was 
associated with enhanced cell death as determined by 
Annexin V/PI staining, and both phenomena were delayed 
when glucose deprivation was avoided by adding 5 mM 
glucose to the media twice a week. A similar decrease in 
the ROS content was obtained by N-acetylcysteine instead 
of glucose during the experiment (data not shown). The 
influence of glucose starvation on ROS accumulation 
was confirmed in a 3-day experiment where pScont cells 
cultivated in absence of glucose accumulated much more 
ROS than pScN-II cells (Figure 4D). The replacement 
of glucose by galactose, which forces cells to perform 
oxidative phosphorylation, yielded similar results as for 
cells without glucose. Similar experiments performed on 
NCI-H292, MIA PaCa-2 and HCT-116 cell models did not 
show any differences between pScont and pScN-II cells 
(data not shown).
Cells with low cN-II expression are sensitive to 
combined hypoxia and glucose deprivation
We further performed xCELLigence experiments 
in hypoxic conditions (1% O2), and observed that pScN-
II cells were clearly more sensitive and died earlier than 
pScont cells (Figure 5). The time of cell death was here 
also dependent on the initial concentration of glucose in 
the culture medium suggesting that tolerance to reduced 
glucose was different under normoxic and hypoxic 
conditions.
If the difference observed in cell survival in hypoxic 
conditions is due to a difference in remaining oxidative 
phosphorylation, the cells could have been expected to 
Figure 5: In vitro cell growth of MDA-MB-231-pScont (■) and -pScN-II (●) cells in hypoxic (1% O2) conditions in presence of 10 mM 
(A) or 5 mM (B) glucose. Cells were seeded at 3000 cells per well in a final volume of 250 μl. Graphs show the normalized cell index during 
time (normalized on 5 hours).
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display different sensitivities to inhibitors of oxidative 
phosphorylation. This was however not the case in our 
MDA-MB-231 models, as the percentage of dead cells 
was similar in pScN-II cells as compared to pScont 
cells after 48 hour exposures to 5 or 50 μM rotenone, a 
mitochondrial complex I inhibitor (Figure 6A).
Finally, we evaluated the ROS content in pScont 
cells and pScN-II cells cultured in hypoxic conditions 
with or without glucose. We observed similar results as 
in normoxia, i.e. pScont cells accumulating higher levels 
of ROS than pScN-II cells in absence of glucose, and 
lower ROS contents for both cell lines when glucose was 
added to the medium during cell growth (Figure 6B). 
These results are consistent with the fact that pScN-II 
cells would have a lower induction of hypoxia-inducible 
factor-1 (HIF-1) as this is dependent both on hypoxia and 
on ROS content [25, 26]. Indeed, if pScN-II cells have 
less ROS in hypoxic conditions, they would have a lower 
induction of HIF-1, and thus a worse adaptability to the 
hypoxic condition as compared to pScont cells.
cN-II downregulated cells have a better defense 
against ROS
As ROS levels were higher in pScont cells despite an 
apparently similar glucose consumption and metabolism, 
we assumed that the antioxidative defense mechanisms 
could be more abundant or more efficient in pScN-II cells. 
We first quantified the relative gene expression of NAD(P)
H quinone dehydrogenase 1 (NQO1), thioredoxin-2 
Figure 6: (A) Percentage of living MDA-MB-231-pScont (black bars) and -pScN-II (grey bars) cells incubated alone or in presence 
of indicated concentrations of rotenone and menadione. Cells were seeded in 6-well plates at 200 000 cells per well in 3 mL of culture 
media, and living cells are AnnexinV and propidium iodide negative. Results are mean values and error bars are standard deviation of three 
independent experiments. (B) Relative ROS content in MDA-MB-231-pScont (■) and -pScN-II (●) cells incubated with 1 mM glucose 
(filled lines) or without glucose (dotted lines) in hypoxic conditions (1% O2). Results are expressed as relative to MFI on day 1 for pScont 
cells incubated with glucose. Cells were seeded at 200 000 cells per well in 6-well plates with 3 mL culture media. Results are mean values 
and error bars are standard deviations of four independent experiments. Means were compared with Student’s t-test and differences were 
statistically significant at day 3 between pScont and pScN-II without glucose, and at day 4 between pScont and pScN-II with 1 mM glucose.
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(TXN2), superoxide dismutase 1 and 2 (SOD1 and SOD2) 
and glutathione S-transferase π (GSTP1). As shown in 
Figure 7A, these genes were expressed either at the same 
level or slightly less in pScN-II cells when cultured in 
presence of glucose. However, after 5 hours of culture in 
absence of glucose, these genes were all found to be more 
expressed in pScN-II cells as compared to pScont cells. 
Similar results were obtained when cells were exposed 
to the positive control menadione, a well-described ROS 
and anti-ROS defense inducer. This is in line with our 
hypothesis that pScN-II cells have a better overall capacity 
to respond to ROS after glucose deprivation.
This increase in gene expression was confirmed at 
the protein level for TXN2 but not for GSTP1 after an 
8 hour incubation in the absence of glucose (Figure 7B). 
Indeed, still no difference was observed when cells were 
cultured in presence of glucose, but TXN2 expression 
increased 2-fold in pScN-II cells cultured in absence 
of glucose. Again, similar results were obtained with 
exposure to menadione.
cN-II downregulation increases the autophagy 
flux
Autophagy can be induced by energy deprivation, 
and contributes to the regeneration of ATP and other 
nutrients in the cells. Therefore, autophagy could also 
explain the metabolic advantages of pScN-II cells as 
Figure 7: (A) Relative gene expression of anti-ROS genes in MDA-MB-231-pScont (left) and -pScN-II (right) cells incubated in presence 
(black bars) or in absence (grey bars) of 25 mM glucose, or in presence of glucose and 20 μM menadione (white bars) for 5 hours. Results 
are expressed as mean values of two independent experiments using pScont cells in presence of glucose as reference, and error bars are 
standard deviation. (B and C) Protein expression of TXN-2 (B, size 12 kDa) and GSTP1 (C, size 24 kDa) and beta-actin (size 42 kDa) 
in MDA-MB-231-pScont and -pScN-II cells cultured in presence (Glc +) or absence (Glc -) of glucose or in presence of glucose and 20 
μM menadione (Mena) for 8 hours. The gels show results from a representative experiment and for the quantification, all samples were 
standardized to the ratio of protein/actin in pScont cells with glucose. The graph shows the mean values ± standard deviation of the 
quantification of bands obtained in three independent experiments. Means were compared with Student’s t-test but not found statistically 
significantly different.
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compared to pScont cells. We investigated whether 
autophagy markers were differentially expressed between 
the two cell lines. As shown in Figure 8, pScN-II cells had 
higher expression of LC3-II, a marker for autophagy flux, 
than pScont cells when cultured in normal culture media. 
As expected, its expression increased after incubation with 
25 mM of 2-deoxyglucose for 16 hours in pScont cells 
whereas this was not the case in pScN-II cells suggesting 
that the autophagy flux was already at its highest level 
in the basal conditions. It is however unclear whether 
autophagy is involved in the differences observed in 
hypoxic conditions.
DISCUSSION
During our work on cN-II over the last 15 years, 
several observations have suggested that this enzyme 
might play major roles in human cells, independently 
from its activity in purine metabolism and sensitivity to 
nucleoside analogues [27]. First, transient inhibition by 
siRNA or by enzymatic inhibitors induce cell death in 
certain cancer cell models [12, 17]. Second, modulation 
of cN-II expression was associated with variations in 
cell growth rate and intracellular energy charge [20, 28]. 
Third, the highly conserved structure of cN-II among 
species, which is not limited to active and regulatory 
sites, suggested interactions with other cellular proteins 
[21]. Using our stable cell models for decreased cN-
II expression, we here show consistent results on the 
implication of this enzyme in the regulation of cellular 
defense to oxidative stress.
Our results from the in vivo experiments show that 
the decrease of cN-II expression favors tumor growth. 
This is to our knowledge the first published data on tumor 
growth of cells with modified cN-II expression. However, 
this is not consistent with the previously reported results 
showing no difference in in vitro proliferation on these 
same cell lines [19] or decreased in vitro cell growth in a 
neuroblastoma model [20]. Enhanced tumor growth in vivo 
is thus not simply explained by enhanced proliferation of 
Figure 8: Protein expression of LC3-II (size 17 kDa) and beta-actin (size 42 kDa) in MDA-MB-231-pScont and -pScN-
II cells cultured in normal media or exposed 16 hours to 2-deoxyglucose. The gel shows result from a representative experiment 
and the graph shows the mean values ± standard deviation of the quantification of bands obtained in four independent experiments. 
*: p<0.005 with Student’s t-test.
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the cell lines in short term in vitro cultures. This difference 
in in vivo growth was however at least partially explained 
by our long term in vitro cell growth experiments. Our 
xCELLigence experiments were performed without 
renewal of culture media, and we showed that glucose 
was a limiting factor in this culture, since the differences 
in growth curves were observed earlier when cells were 
seeded in lower glucose concentrations (Figure 2). As this 
was not due to a difference in the glucose consumption 
between our cell lines, we proposed that the cN-II 
downregulation had induced a better capacity to respond 
to this low glucose environment. This could indeed be the 
case in the tumors as both cell lines grow similarly in the 
beginning, but diverge once they have reached a certain 
volume, eventually corresponding to a stage at which 
the tumor is poorly irrigated and the microenvironment 
is depleted of certain metabolites. However, such tumors 
would also be rather hypoxic, and thus more prone to cell 
death as suggested by our in vitro data. Unfortunately, due 
to technical issues, we were not able to obtain interpretable 
results on the xCELLigence apparatus for the glucose-
dependency of NCI-H292, MIA-PaCa 2 and HCT-116 
cells.
We also showed that the ROS content was much 
higher in control cells than in pScN-II cells when cells 
lacked glucose in the media either after long term culture 
or by incubating them directly without glucose. ROS-
production by NADPH oxidase and mitochondrion has 
been shown to be induced by glucose deprivation in cancer 
cells and associated to subsequent cell death [29]. As, in 
our model, the highest ROS content was associated with 
a higher cell death, we conclude that this ROS content 
can directly explain the observed differences in cell 
death between our two cell lines. Furthermore, pScN-II 
cells displayed a better defense against ROS with both 
an enhanced induction of TXN2-expression and more 
autophagy.
One explanation to the observed glucose-
deprivation-related differences between MDA-MB-231-
pScont and -pScN-II cells could be the action of cN-II on 
metabolites of nicotinamide adenine dinucleotide (NAD). 
Indeed, it has been shown first in yeasts [30] and later in 
humans [31] that the mononucleotides of nicotinamide 
(NMN) and nicotinic acid (NAMN) are substrates for 
both cytosolic pyrimidine preferring 5’-nucleotidase 
(human cN-III and yeast Sdt1) and the purine preferring 
5’-nucleotidase (human cN-II and yeast Isn1). Thus, it is 
possible that cN-II expressing cells have overall a lower 
level of NAD and its reduced form NADH (and thus of 
NADP) due to a higher degradation of their precursors, 
and consequently a poorer defense towards ROS that 
are produced in the presence of low glucose. The recent 
observation of an association between oxidative stress and 
an IMP/GMP-preferring 5’-nucleotidase (yktC) in Bacillus 
subtilis, strengthens this hypothesis [32].
When cells were grown under hypoxic conditions, 
the decrease of cN-II expression was shown to be 
associated with a higher sensitivity to the disappearance of 
glucose in the media. This could be explained by a higher 
ROS content in these cells. Indeed, it has been proposed 
that in hypoxic conditions, the ROS production is higher 
in cells with high NADH level [33]. This would again 
increase the glucose consumption by regulating GLUT-4 
expression on the cell membrane as described in skeletal 
muscle cells [34]. This would be consistent with our 
hypothesis stating that pScN-II cells have a higher level 
of NADH because of a lower catabolism of its precursors. 
However, this was not the case in our ROS content 
quantification assays in cells grown in hypoxic conditions, 
suggesting another and yet unknown mechanism for this 
increased sensitivity to low glucose concentrations in 
hypoxia. It has been shown in a particular model that 
concomitant hypoxia and low glucose induced unfolded 
protein response [35]. This could indeed be the case 
also in our models, but additional experiments would be 
needed to confirm this.
The fact that pScN-II cells do not accumulate more 
ROS than pScont cells in hypoxic conditions whereas 
they die earlier (as shown by xCELLigence experiments 
in hypoxic conditions), could indicate that in normoxic 
conditions, a difference in ROS content is involved in the 
differential behavior between the two cell lines, whereas 
in hypoxic conditions, this difference is ROS-independent. 
We showed here that the pScN-II cells have a better 
overall anti-ROS defense, with a particular involvement 
of thioredoxin 2 and autophagy. The detailed mechanism 
by which these cells acquire this phenotype is not yet 
understood, but we believe that cells with downregulated 
cN-II expression will adapt through an increase of 
phosphorylated nicotinamide derivatives or through an 
adapted kinetics in AMPK activation. Ongoing studies 
should help us decipher this particular mechanism. Our 
results might have clinical relevance in settings where 
cancer patients are treated with metabolic inhibitors 
targeting directly or indirectly glucose metabolism. 
Indeed, such therapeutic approaches will be more efficient 
on cancer cells expressing high levels of cN-II than on 
cells with low levels of cN-II, making this protein a 
potential marker for response to treatment as already 
described in other clinical settings [8].
MATERIALS AND METHODS
Cells and culture
In this study we used human cancer cell lines from 
lung (NCI-H292), pancreas (MIA PaCa-2), colon (HCT-
116) and breast (MDA-MB-231). Cells were transfected 
to express either a shRNA against cN-II (pScN-II cells) or 
control shRNA (pScont). General cell culture conditions 
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and the development of transfected cell lines have been 
previously described [9, 19].
cN-II activity assessment
cN-II activity in transfected models was assessed 
using a validated non-radioactive method of liquid 
chromatography coupled to a tandem mass spectrometry 
as described elsewhere [9].
In vivo tumor growth
Female severe combined immunodeficiency CB17 
mice (2-4 months old, approximately 20 g, Charles 
River, L’Arbresle, France) were injected with indicated 
amount of cells subcutaneously on day 1. Tumor size 
was measured twice a week and mice were euthanized 
when the tumor volume was >1500 mm3. The protocol 
for experiments in mice was approved by the University 
of Lyon Animal Ethics Committee. Mean tumor volumes 
were compared with Student’s t-test.
Cell proliferation and adherence
The xCELLigence system (ACEA Biosciences) 
was used to concomitantly determine cell proliferation 
and adherence in real-time analysis. Cells were seeded 
(3000 cells per well, 250 μl of media) in 16-wells E-plates 
as indicated by the manufacturer and the cell index was 
recorded every 15 minutes for 24 hours then every 30 
minutes up to 20 days. Cell proliferation and survival were 
also assessed by direct counting of cells both adhered to 
the flask and in the cell culture media using a Cellometer 
Auto T4 (Nexcelom Bioscience).
Quantification of glucose and lactate in cell 
media
Cells were seeded in 6-well plates (90 000 cells per 
plate) in media containing 10 mM glucose and incubated 
at 37 °C for indicated times. At each time point, cells 
were trypsinized and counted, and the supernatant was 
recovered for dosage of glucose and lactate. Glucose 
was quantified by the measurement of NADPH produced 
during enzymatic reactions, and lactate by its conversion 
to pyruvate and hydrogen peroxide followed by 
the conversion of ABTS into a chromogen as described 
earlier [36].
Cell survival assay
Cell survival was assessed by the quantification 
of Annexin V / propidium iodide negative cells on a 
FACScalibur flow cytometer using Annexin-V-FLUO 
Staining kit (Roche) as indicated by the manufacturer 
and after culture in indicated conditions. Adherent 
and spontaneously detached cells were pooled for this 
analysis.
Quantification of intracellular reactive oxygen 
species
The content of reactive oxygen species (ROS) 
in cells was determined using an oxidation sensitive 
fluorescent dye (H2DCFDA, Life Technologies). Cells 
were cultured as indicated and for ROS quantification, 
cells were washed with PBS, incubated 30 minutes at 37 
°C with 5 μM H2DCFDA, washed twice with PBS and 
incubated with complete media for 10 minutes at 37 °C. 
Finally, cells were washed twice with PBS, trypsinized, 
centrifuged (5 minutes, 300 g) and resuspended in 200 
μl PBS. ROS were measured by flow cytometry on a 
FACScalibur (λ
ex/em
: 490 / 530 nm) and compared to the 
autofluorescence of cells incubated with PBS instead of 
H2DCFDA.
Western blot analyses
Proteins were extracted from cell pellets with cold 
RIPA buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% 
Triton X-100, 1% sodium deoxycholate, 1 M DTT, 1 M 
NaF, protease inhibitor cocktail, phosphatase inhibitors 
buffer and 100 mM sodium orthovanadate) or buffer A (20 
mM Tris-HCl pH 6.8, 1 mM MgCl2, 2 mM EGTA, 0.5% 
NP40, 2% protease inhibitor cocktail) on ice for 60 (RIPA) 
or 15 (buffer A) minutes followed by centrifugation (15 
minutes, 12 000 g, 4 °C). Proteins were separated by SDS-
PAGE and transferred onto nitrocellulose membrane using 
the iBlot® system (Life Technologies). Membranes were 
incubated with specific antibodies for LC3-II (NB100-
2220, 1/500; Novus Biologicals), GSTP1 (A5691, 1/500; 
NeoBioLab), TXN2 (A6782, 1/500; NeoBioLab) and 
beta-actin (clone AC-15, 1/5000; Sigma) and anti-murine 
antibody (IRDye® 800CW, 1/5000; LI-COR Biosciences) 
or anti-rabbit antibody (IRDye® 680, 1/5000; LI-COR 
Biosciences), and protein expression was visualized using 
the Odyssey infrared system (LI-COR Biosciences). 
Bands were quantified using the Odyssey system, and the 
results are presented as ratio of the expression of proteins 
of interest to beta-actin expression.
Quantitative RT-PCR
Total RNA was extracted from cells using RNeasy 
mini kit (Qiagen) as described by the manufacturer. 
Reverse transcription was performed with Moloney 
leukemia virus reverse transcriptase and quantitative PCR 
on a LightCycler thermal cycler (Roche) in the following 
conditions: 5 minutes initial denaturation at 95 °C follow 
by 40 cycles of 10 seconds at 95 °C, 10 seconds at 60 
°C and 10 seconds at 72 °C and terminated by a melting 
curve from 70 °C to 95 °C. Primers were: NQO1 forward: 
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5’-ATGTATGACAAAGGACCCTTCC-3’; NQO1 reverse 
5’-TCCCTTGCAGAGAGTACATGG-3’; TXN forward 
5’-TTACAGCCGCTCGTCAGA-3’; TXN reverse 
5’-AAGGCTTCCTGAAAAGCAGTC-3’; SOD1 forward 
5’-TCATCAATTTCGAGCAGAAGG-3’; SOD1 reverse 
5’-GCAGGCCTTCAGTCAGTCC-3’; SOD2 forward 
5’-AAGTACCAGGAGGCGTTGG-3’; SOD2 reverse 
5’-TGAACTTCAGTGCAGGCTGA-3’; GSTP1 forward 
5’-GGCAACTGAAGCCTTTTGAG-3’ and GSTP1 
reverse 5’-GGCTAGGACCTCATGGATCA-3’. Relative 
quantification was calculated using the ΔΔCT-method and 
human ribosomal 28S RNA as reference gene.
Autophagy flux assessment
Cells (3.106 per dish) were plated in 10 cm culture 
dishes and exposed or not to 25 mM 2-deoxyglucose 
(Sigma) for 16 hours before cells were subjected to protein 
extraction and Western blot analysis as indicated above.
Abbreviations
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